| Deborah Liechty, PHARMD | |
|
1159 S Central Ave, Sidney, MT 59270-5219 | |
| (406) 482-6401 | |
| Not Available |
| Full Name | Deborah Liechty |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1159 S Central Ave, Sidney, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265907091 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S023366 (Arizona) | Secondary |
| 183500000X | Pharmacist | PHA-PHA-LIC-55379 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Deborah Liechty, PHARMD 1159 S Central Ave, Sidney, MT 59270-5219 Ph: () - | Deborah Liechty, PHARMD 1159 S Central Ave, Sidney, MT 59270-5219 Ph: (406) 482-6401 |
News Archive
According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.
Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent. New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.
Men with serious injuries, such as traumatic brain injury or spinal cord injury, must deal with a range of emotions.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
› Verified 3 days ago
Timothy Patrick Wagner, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 402 E Main St, Sidney, MT 59270 Phone: 406-482-1992 Fax: 406-482-5338 | |
Emily Marin Madsen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 402 E Main St, Sidney, MT 59270 Phone: 406-482-1420 | |
Jack Tidaback, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 214 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-6563 Fax: 406-488-2231 | |
Sandra Eileen Olson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 402 E Main St, Sidney, MT 59270 Phone: 406-482-1420 Fax: 406-482-5338 | |
Dr. Lynn Wayne Beyerle, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 216 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2131 Fax: 406-488-2238 | |
Monte John Schumacher, BS Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 216 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2164 |